We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

I’m expecting strong updates from these dividend stocks on Monday!

Royston Wild discusses two income heroes he expects to release strong trading updates next week.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Those looking to build big income flows at low cost should pay newspaper publisher Reach (LSE: RCH) close attention. This a share that carries a bulky 4% forward dividend yield and a rock-bottom forward P/E ratio of 4.5 times.

Reach isn’t quite out of the woods just yet. The stresses across its print division that create its low valuation remain significant. It’s why the small-cap saw like-for-like revenues across its physical titles drop 7.3% during the five months to November.

Should you buy Dechra Pharmaceuticals Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

However, the rate of decline is steadily improving. Meanwhile the reasoning for its increased focus on digitalisation is becoming much more apparent. Digital revenues boomed 14% in the period to November versus the healthy 9.3% rise of a year earlier.

Marketing budgets are on the march

I’m excited to see what additional progress Reach’s print and digital titles have made more recently. Full-year financials are slated for Monday (February 24), and I reckon more share price gains could be built following these results.

Reach has already soared almost 200% in value over the past 12 months. That low rating, though, leaves plenty of space for more meaty share price gains.

Recent better news on the state of the British advertising sector has raised my hopes of a strong set of numbers from Reach. According to the latest IPA Bellwether report, a net balance of +4% of companies raised their total marketing budgets in the fourth quarter of 2019.

And the broader outlook for 2020 looks quite promising too. The study, published by IHS Markit and the Institute of Practitioners in Advertising, showed that a net balance of +15.7% of firms expect their total marketing spend targets to be increased, up markedly from the net balance of +3.4% reported a year earlier.

The right medicine for dividend growth

I’m also expecting positive news when Dechra Pharmaceuticals (LSE: DPH) releases interim results on Monday.

The business, which provides medicines for companion animals and livestock, doesn’t offer the same sort of dividends as Reach. Indeed, the forward yield sits at just 1.2%. That said, the rate at which it is raising annual payouts still makes it a great pick for income chasers. The full-year dividend for the last fiscal year (to June 2019) was hiked 24%, for example.

Dechra certainly reminded the market of its exceptional growth prospects when it updated in January. Then it said that even though supply-side issues hammered performance in North America, the strength of its European operations (where net revenues jumped 13%) allowed group net sales to rise a chubby 7%.

Investor appetite for the FTSE 250 firm could also be boosted if Dechra advises that the “significant progress” it has previously made in solving those supply problems has continued.

Dechra is a company that doesn’t come cheap. Right now it trades on a forward P/E multiple of 30 times. I believe however that this is a fair reflection of the brilliant profits opportunities that the fast-growing animal care industry provides.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using smartphone at home, watching stock charts.
Growth Shares

At 112p, where next for the Lloyds share price? 168p or 56p?

Jon Smith mulls over the direction going forward for the Lloyds share price, and explains why two very different scenarios…

Read more »

Investing Articles

This dividend stock has a 7.3% yield, and Stocks and Shares ISA investors are buying!

Looking to move from a Cash ISA to a Stocks and Shares ISA to target passive income? Alan Oscroft has…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Could Rolls-Royce shares lock in another 34% gain before Christmas?

Mark Hartley takes a look at some of the more optimistic price targets for Rolls-Royce, and considers a best-case scenario.…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

Investec vs Aberdeen: which is the better income stock to buy?

Aiming to boost the average yield of his income portfolio, Mark Hartley's looking for new income stocks to buy on…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Down 41% since January, this quality S&P 500 stock is stinking out my ISA

The tide's turned against this S&P 500 robotics stock. Is it time to dump it? Or is there a no-brainer…

Read more »

GSK scientist holding lab syringe
Investing Articles

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

GSK shares are currently trading almost 20% below their 2026 highs. Is there potential for a rebound over the next…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up nearly 1,400% in 5 years! But are Rolls-Royce shares still secretly undervalued?

After skyrocketing, Rolls-Royce shares are now near an all-time high, but could the engineering giant still have more room to…

Read more »

Happy senior couple hugging and enjoying retirement at home
Investing Articles

By mid-2027, analysts expect £5,000 in Barclays shares to be worth…

Barclays shares have outperformed the FTSE 100 by a wide margin over the last year. And City analysts expect to…

Read more »